Do you want to read an article? Please log in or register.
Circulating Plasma Biomarkers of Survival in Anti-fibrotic Treated Patients with Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
RECOMMENDED
Related content
COMMENTED
Pulmonary Fibrosis
Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials
Lancet Respir Med.
Neighbors M, Cabanski CR, Ramalingam TR, Sheng XR, Tew GW, Gu C, Jia G, Peng K, Ray JM, Ley B, Wolters PJ, Collard HR, Arron JR
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Exhaled Biomarkers in Idiopathic Pulmonary Fibrosis-A Six-Month Follow-Up Study in Patients Treated with Pirfenidone
★ 1
Recommended by
Dr Martin Frey, Faculty Member
J Clin Med.
Jaskiewicz K, Mycroft K, Maskey-Warzechowska M, Paralusz K, Siemiez N, Nejman-Gryz P, Barnas M, Krenke R, Gorska K
doi: 10.3390/jcm9082523.
RECOMMENDED
Pulmonary Fibrosis
Adoption of the Anti-Fibrotic Medications Pirfenidone and Nintedanib for Patients with Idiopathic Pulmonary Fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Ann Am Thorac Soc
Dempsey TM, Payne S, Sangaralingham L, Yao X, Shah ND, Limper AH
doi: 10.1513/AnnalsATS.202007-901OC
COMMENTED
Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial
Lancet Respir Med.
Raghu G, Pellegrini CA, Yow E, Flaherty KR, Meyer K, Noth I, Scholand MB, Cello J, Ho LA, Pipavath S, Lee JS, Lin J, Maloney J, Martinez FJ, Morrow E, Patti MG, Rogers S, Wolters PJ, Yates R, Anstrom KJ, Collard HR
doi: 10.1016/
RECOMMENDED
Pulmonary Fibrosis
Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Eur Respir Rev.
Khor YH, Ng Y, Barnes H, Goh NSL, McDonald CF, Holland AE
doi: 10.1183/16000617.0158-2019.
RECOMMENDED
Pulmonary Fibrosis
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Respir Res.
Holtze CH, Freiheit EA, Limb SL, Stauffer JL, Raimundo K, Pan WT, Flaherty KR, Kim HJ
doi: 10.1186/s12931-020-1315-4.
RECOMMENDED
Pulmonary Fibrosis
Clinical Effectiveness of the Anti-Fibrotic Medications for Idiopathic Pulmonary Fibrosis
Am J Respir Crit Care Med.
Dempsey TM, Sangaralingham LR, Yao X, Sanghavi D, Shah ND, Limper AH
doi: 10.1164/rccm.
CXCL14 is a candidate biomarker for Hedgehog signalling in idiopathic pulmonary fibrosis
Thorax.
Jia G, Chandriani S, Abbas AR, DePianto DJ, N'Diaye EN, Yaylaoglu MB1, Moore HM, Peng I, DeVoss J, Collard HR, Wolters PJ, Egen JG, Arron JR
doi: 10.1136/thoraxjnl-
Pulmonary Fibrosis
Breath biomarkers in idiopathic pulmonary fibrosis: a systematic review
Respir Res.
Hayton C, Terrington D, Wilson AM, Chaudhuri N, Leonard C, Fowler SJ
doi: 10.1186/s12931-019-0971-8.